StockNews.AI

INVESTOR ALERT: Investigation of Travere Therapeutics, Inc. (TVTX) by Holzer & Holzer, LLC

StockNews.AI • 4 hours

TVTX
High Materiality8/10

Information

ATLANTA, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Travere The...

Original source

AI Summary

Holzer & Holzer is investigating Travere Therapeutics for possible securities law violations after the FDA extended the review timeline for FILSPARI®. This news has negatively impacted Travere's stock price, prompting calls for investors to explore their legal options.

Sentiment Rationale

Uncertainty around regulatory approval and legal scrutiny typically leads to downward price pressure; historical examples indicate a drop in stock values during extended FDA review processes.

Trading Thesis

Expect further stock price volatility in the near term as investors react to news.

Market-Moving

  • FDA review timeline extension could hinder business prospects for Travere.
  • Legal investigations typically incite panic selling among investors.
  • Continued scrutiny may pressure Travere's stock price further downward.
  • Potential for legal action might influence investor sentiment negatively.

Key Facts

  • Holzer & Holzer investigates Travere for potential securities law violations.
  • FDA extended review timeline for Travere's FILSPARI® application.
  • Stock price of Travere fell following the FDA news.
  • Investors who lost money are encouraged to act legally.
  • Holzer & Holzer specializes in representing shareholders in litigation.

Companies Mentioned

  • Travere Therapeutics, Inc. (TVTX): Facing scrutiny which may impact stock price and investor confidence.

Corporate Developments

This falls under Corporate Developments due to the significant legal and regulatory implications affecting Travere's operations and investor communications.

Investigation Launched into Travere Therapeutics (TVTX) by Holzer & Holzer, LLC

ATLANTA, Jan. 14, 2026 (GLOBE NEWSWIRE) — Holzer & Holzer, LLC has initiated an investigation concerning Travere Therapeutics, Inc. (NASDAQ: TVTX) to determine if the Company adhered to federal securities laws.

Details of the Investigation

On January 13, 2026, Travere Therapeutics revealed that the U.S. Food and Drug Administration (FDA) has extended the review timeline for its supplemental New Drug Application related to FILSPARI® (sparsentan) in the treatment of focal segmental glomerulosclerosis. This announcement has prompted a decline in the stock price of TVTX.

If you have purchased stock in Travere and experienced a financial loss, you are encouraged to reach out to Holzer & Holzer for guidance on your legal rights. Investors can contact:

Holzer & Holzer's Commitment to Investors

Holzer & Holzer, LLC is recognized as a top-rated securities litigation law firm by ISS for the years 2021, 2022, 2023, and 2025. The firm is dedicated to representing shareholders and investors across the nation in various types of litigation, including shareholder class actions and derivative cases.

Founded in 2000, Holzer & Holzer has successfully recovered hundreds of millions of dollars for shareholders who have fallen victim to fraud and corporate malpractice.

For more information about the firm, visit www.holzerlaw.com.

Contact Information

If you are impacted by the recent developments regarding Travere Therapeutics and would like to explore your legal options, please contact:

Corey Holzer, Esq.

Toll-free: (888) 508-6832

Email: cholzer@holzerlaw.com

This communication has been sponsored by Holzer & Holzer, LLC, with Corey Holzer being responsible for its content.

Related News